Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply

N Engl J Med. 2021 Jul 15;385(3):288. doi: 10.1056/NEJMc2107809. Epub 2021 Jun 9.

Authors

An Vandebosch¹, Jerald Sadoff², Macaya Douoguih²

Affiliations

¹ Janssen Research and Development, Beerse, Belgium.
² Janssen Vaccines and Prevention, Leiden, the Netherlands mdouogui@its.jnj.com.

PMID: 34107179
DOI: 10.1056/NEJMc2107809

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Neutralizing
COVID-19 Vaccines*
COVID-19*
Humans
Immunogenicity, Vaccine
SARS-CoV-2

Substances

Antibodies, Neutralizing
COVID-19 Vaccines